SomnoMed Fiscal Q2 Revenue Grows 20%, Shares Rise 10%

MT Newswires Live
01-24

SomnoMed (ASX:SOM) said its revenue for the quarter ended Dec. 31, 2024, grew 20% year-over-year to AU$28.5 million, according to a Friday Australian bourse filing.

Its revenue in the fiscal second quarter reported a jump in all geographies, with North America and Asia-Pacific achieving double-digit increases.

It updated its guidance for the fiscal year ending June 30, now expecting a revenue of about AU$105 million as well as earnings before interest, taxes, depreciation, and amortization of between AU$7 million to AU$9 million.

The firm's shares rose 10% in recent trading on Friday.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10